Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Correlation between the Degree of Bone Marrow Involvement and the Results of NGS in Plasma Cell Neoplasms

Ekaterina Rebmann Chigrinova, MD PhD, Naomi A. Porret, PhD, Gertrud Wiedemann, PhD, Martin Andres, MD, Yara Banz, MD PhD, Myriam Legros, Matthias Pollak, MD, Elisabeth Oppliger Leibundgut, Thomas Pabst, MD, Ulrike Bacher

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-142009

Published: 2020

Journal Articles

High-Dose Chemotherapy with Bendamustin and Melphalan Improves the Rate of Complete Remission in Myeloma Patients in First Remission Compared to Standard Melphalan Alone

Sarah Farag, Ulrike Bacher, Myriam Legros, Daniel Betticher, Jean-Marc Lüthi, Thomas Egger, Thilo Zander, MD, Barbara Jeker, Thomas Pabst, MD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-141545

Published: 2020

Journal Articles

Targeting CD70 with Cusatuzumab Eliminates Acute Myeloid Leukemia Stem Cells in Humans

Blood (2019) 134 (Supplement_1): 234.

https://doi.org/10.1182/blood-2019-129916

Published: 2019

Journal Articles

Rebound Thrombocytosis after Induction Chemotherapy Is a Strong Biomarker for Favorable Outcome in AML Patients

Thomas Pabst, MD, Bianca R Schnell, Ulrike Bacher, Barbara Jeker, Yara Banz, Urban Novak, Katja - Seipel

Blood (2019) 134 (Supplement_1): 5101.

https://doi.org/10.1182/blood-2019-127984

Published: 2019

Journal Articles

Autologous Stem Cell Transfusions on Multiple Days in Patients with Multiple Myeloma - Does It Matter?

Thomas Pabst, MD, Sebastian Moser, Ulrike Bacher, Barbara Jeker, Behrouz Mansouri Taleghani, Prof., Urban Novak

Blood (2019) 134 (Supplement_1): 3252.

https://doi.org/10.1182/blood-2019-127940

Published: 2019

Journal Articles

How to Collect the Minimum-Targeted CD3+ Cells for CAR-T Therapy- the Bern Approach

Katarzyna Aleksandra Jalowiec, Thomas Pabst, MD, Christoph Bocksrucker, Claudio Brunold, Barbara Jeker, Gabriela M Baerlocher, MD, Urban Novak, Ulrike Bacher, Michael Daskalakis, MD, Behrouz Mansouri, MD, Sacha S Zeerleder, MD PhD

Blood (2019) 134 (Supplement_1): 2457.

https://doi.org/10.1182/blood-2019-126534

Published: 2019

Journal Articles

A Randomized Evaluation of Vinorelbine Versus Gemcitabine Chemotherapy Mobilization of Stem Cells in Myeloma Patients

Barbara Jeker, Sarah Farag, Urban Novak, Ulrike Bacher, Behrouz Mansouri Taleghani, Qiyu Li, Thomas Pabst, MD

Blood (2019) 134 (Supplement_1): 1963.

https://doi.org/10.1182/blood-2019-127848

Published: 2019

Journal Articles

Rituximab Maintenance Treatment for a Maximum of 5 Years in Follicular Lymphoma: Final Results of the Randomized Phase III Trial SAKK 35/03

Christian Taverna, MD, Giovanni Martinelli, MD, Felicitas Hitz, MD, Walter Mingrone, MD, Thomas Pabst, MD PhD, Lidija Cevreska, MD PhD, Auro del Giglio, MD, Anna Vanazzi, MD, Daniele Laszlo, MD, Johann Raats, Daniel Rauch, Daniel Vorobiof, Andreas Lohri, MD, Emanuele Zucca, Celine Rueegsegger, Stephanie - Rondeau, Corinne Rusterholz, Michele Ghielmini

Blood (2018) 132 (Supplement 1): 1601.

https://doi.org/10.1182/blood-2018-99-116864

Published: 2018

Journal Articles

Argx-110 Targeting CD70, in Combination with Azacitidine, Shows Favorable Safety Profile and Promising Anti-Leukemia Activity in Newly Diagnosed AML Patients in an Ongoing Phase 1/2 Clinical Trial

Adrian F Ochsenbein, MD, Carsten Riether, PhD, Ulrike Bacher, Rouven Müller, MD, Sabine Höpner, PhD, Yara Banz, Magdalena Hinterbrandner, Msc, Mario Bargetzi, MD, Markus G. Manz, MD, Luc Van Rompaey, PhD, Mahan Moshir, MSc, Tim Delahaye, MSc, Domenica Gandini, MD PhD, Ellen Erzeel, Anna Hultberg, PhD, Samson Fung, MD, Hans De Haard, PhD, Nicolas Leupin, MD, Thomas Pabst, MD PhD

Blood (2018) 132 (Supplement 1): 2680.

https://doi.org/10.1182/blood-2018-99-118302

Published: 2018

Journal Articles

Prospective Long-Term Follow-up after First-Line Subcutaneous Cladribine Treatment in Patients with Hairy Cell Leukemia. a Study of the SAKK (Swiss Group for Clinical Cancer Research)

Rudolf A. Benz, MD, Kornelius Arn, MD, Martin Andres, Thomas Pabst, MD PhD, Urban Novak, Felicitas Hitz, MD, Reinhard Zenhäusern, Yves Chalandon, MD PhD, Ulrich Mey, MD, Sabine Blum, Daniel Rauch, Willy Nettekoven, Nathan Cantoni, MD, Mario Bargetzi, MD, Alix O'Meara, MD, Andreas Lohri, MD, Simona Berardi, PhD BSc, Qiyu Li, Georg Stussi, MD

Blood (2018) 132 (Supplement 1): 2875.

https://doi.org/10.1182/blood-2018-99-114301

Published: 2018

Journal Articles

Melphalan Dose in Myeloma Patients over 65 Years of Age Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation

Guido Ghilardi, MD, Thomas Pabst, MD, Barbara Jeker, MD, Rouven Müller, MD, Anne Cairoli, MD, Antonia Mueller, MD, Mario Bargetzi, MD, Felicitas Hitz, MD, Helen Baldomero, Dominik Heim, MD, Davide Rossi, MD PhD, Michele Ghielmini, MD, Erika Lerch, MD, Urs Schanz, MD, Jakob R. Passweg, MDMS, Georg Stussi, MD, Martina Kleber, MD, Bernhard Gerber

Blood (2017) 130 (Supplement 1): 3297.

https://doi.org/10.1182/blood.V130.Suppl_1.3297.3297

Published: 2017

Journal Articles

Optimizing the Pretransplant Regimen for Autologous Stem Cell Transplantation in Acute Myelogenous Leukemia : Better Outcomes with Busulfan and Melphalan Compared with Busulfan and Cyclophosphamide in High Risk Patients Autografted in First Complete Remission

Norbert Claude Gorin, MDPhD, Myriam Labopin, MD, Didier Blaise, Pierre-Yves Dumas, MD, Thomas Pabst, MD, Silvia Maria Trisolini, William Arcese, MD, Mohamad Mohty, MD PhD, Arnon Nagler, MD

Blood (2017) 130 (Supplement 1): 338.

https://doi.org/10.1182/blood.V130.Suppl_1.338.338

Published: 2017

Journal Articles

Nelfinavir and Lenalidomide/Dexamethasone in Patients with Lenalidomide-Refractory Multiple Myeloma. A Phase I/II Trial — SAKK 39/10

Felicitas - Hitz, MD, Thomas - Pabst, MD, Dagmar - Hess, MD, Marianne Kraus, Lenka Besse, Urban Novak, MD, Katja - Seipel, MD, Stephanie - Rondeau, Silvia - Stüdeli, Simona Berardi, MD, Samaras Panagiotis, MD, Ulrich Mey, MD, Christoph Driessen, MD

Blood (2017) 130 (Supplement 1): 1884.

https://doi.org/10.1182/blood.V130.Suppl_1.1884.1884

Published: 2017

Journal Articles

Prospective Molecular MRD Detection By NGS: A Powerful Independent Predictor for Relapse and Survival in Adults with Newly Diagnosed AML

Blood (2017) 130 (Supplement 1): LBA-5.

https://doi.org/10.1182/blood.V130.Suppl_1.LBA-5.LBA-5

Published: 2017

Journal Articles

Blocking CD70/CD27 Signaling in Combination with Hypomethylating Agents Eradicates Human CD34 + AML Stem and Progenitor Cells in Vitro and In Vivo

Magdalena Hinterbrandner, Msc, Nils Maria Kallen, Ursina Lüthi, Thomas Pabst, MD, Luc Van Rompaey, PhD, Nicolas Leupin, MD, Hans De Haard, PhD, Adrian F Ochsenbein, MD, Carsten Riether, PhD

Blood (2017) 130 (Supplement 1): 2652.

https://doi.org/10.1182/blood.V130.Suppl_1.2652.2652

Published: 2017

Journal Articles

Prevention of Venous Thrombotic Events in Adult Patients with Acute Lymphoblastic Leukemia Treated in a Pediatric-Inspired Protocol - a Graall Study

Corentin Orvain, Marie Balsat, MD, Véronique Lhéritier, Emmanuelle Tavernier, Jean-Pierre Marolleau, MD PhD, Thomas Pabst, MD PhD, Patrice Chevallier, MD PhD, Noémie De Gunzburg, MD, Victoria Cacheux, Francoise Huguet, MD, Sylvain Chantepie, MD, Denis Caillot, Yves Chalandon, MD, Jamilé Frayfer, MD, Caroline Bonmati, MD, Nicolas Boissel, MD PhD, Hervé Dombret, MD PhD, Norbert Ifrah, Mathilde Hunault-Berger, MD PhD

Blood (2016) 128 (22): 2776.

https://doi.org/10.1182/blood.V128.22.2776.2776

Published: 2016

Journal Articles

The HIV Protease Inhibitor Nelfinavir in Combination with Bortezomib and Dexamethasone (NVd) Has Excellent Activity in Patients with Advanced, Proteasome Inhibitor-Refractory Multiple Myeloma: A Multicenter Phase II Trial (SAKK 39/13)

Christoph Driessen, MD PhD, Rouven Müller, MD, Urban Novak, MD, Nathan Cantoni, MD, Daniel Betticher, Nicolas Mach, Michael Gregor, Panagiotis Samaras, MD, Catherine Berset, Stephanie Rondeau, Hanne Hawle, MD, Felicitas Hitz, MD, Thomas Pabst, MD PhD, Thilo Zander, MD

Blood (2016) 128 (22): 487.

https://doi.org/10.1182/blood.V128.22.487.487

Published: 2016

Journal Articles

The Upper Age Limit for a Pediatric-Inspired Therapy in Younger Adults with Ph-Negative Acute Lymphoblastic Leukemia (ALL)? Analysis of the Graall-2005 Study

Blood (2016) 128 (22): 762.

https://doi.org/10.1182/blood.V128.22.762.762

Published: 2016

Journal Articles

Stem Cell Mobilization Chemotherapy with Gemcitabine Is Effective and Safe in Myeloma Patients with Bortezomib Induced Neurotoxicity

Beatrice U. Mueller, MD, Sandra Keller, MD, Katja Seipel, PhD, Behrouz Mansouri Taleghani, MD, Thomas Pabst, MD

Blood (2015) 126 (23): 5436.

https://doi.org/10.1182/blood.V126.23.5436.5436

Published: 2015

Journal Articles

SAKK 65/08: A Phase I Dose Escalation Study of Bortezomib in Combination with Nelfinavir in Patients with Advanced Hematologic Malignancies

Christoph Driessen, MD, Jürgen Bader, Marianne Kraus, PhD, Markus Jörger, MD PhD, Hilde Rosing, PhD, Gregoire Berthod, MD, Felicitas Hitz, MD, Catherine Berset, PhD, Alexandros Xyrafas, Hanne Hawle, MD, Hermann S Overkleeft, PhD, Christiana Sessa, MD, Alwin Huitema, PhD, Ulrich JM Mey, Thomas Pabst, MD, Roger von Moos, MD, Dagmar Hess, MD

Blood (2014) 124 (21): 4747.

https://doi.org/10.1182/blood.V124.21.4747.4747

Published: 2014

NARROW

Correlation between the Degree of Bone Marrow Involvement and the Results of NGS in Plasma Cell Neoplasms

High-Dose Chemotherapy with Bendamustin and Melphalan Improves the Rate of Complete Remission in Myeloma Patients in First Remission Compared to Standard Melphalan Alone

Targeting CD70 with Cusatuzumab Eliminates Acute Myeloid Leukemia Stem Cells in Humans

Rebound Thrombocytosis after Induction Chemotherapy Is a Strong Biomarker for Favorable Outcome in AML Patients

Autologous Stem Cell Transfusions on Multiple Days in Patients with Multiple Myeloma - Does It Matter?

How to Collect the Minimum-Targeted CD3+ Cells for CAR-T Therapy- the Bern Approach

A Randomized Evaluation of Vinorelbine Versus Gemcitabine Chemotherapy Mobilization of Stem Cells in Myeloma Patients

Rituximab Maintenance Treatment for a Maximum of 5 Years in Follicular Lymphoma: Final Results of the Randomized Phase III Trial SAKK 35/03

Argx-110 Targeting CD70, in Combination with Azacitidine, Shows Favorable Safety Profile and Promising Anti-Leukemia Activity in Newly Diagnosed AML Patients in an Ongoing Phase 1/2 Clinical Trial

Prospective Long-Term Follow-up after First-Line Subcutaneous Cladribine Treatment in Patients with Hairy Cell Leukemia. a Study of the SAKK (Swiss Group for Clinical Cancer Research)

Melphalan Dose in Myeloma Patients over 65 Years of Age Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation

Optimizing the Pretransplant Regimen for Autologous Stem Cell Transplantation in Acute Myelogenous Leukemia : Better Outcomes with Busulfan and Melphalan Compared with Busulfan and Cyclophosphamide in High Risk Patients Autografted in First Complete Remission

Nelfinavir and Lenalidomide/Dexamethasone in Patients with Lenalidomide-Refractory Multiple Myeloma. A Phase I/II Trial — SAKK 39/10

Prospective Molecular MRD Detection By NGS: A Powerful Independent Predictor for Relapse and Survival in Adults with Newly Diagnosed AML

Blocking CD70/CD27 Signaling in Combination with Hypomethylating Agents Eradicates Human CD34 + AML Stem and Progenitor Cells in Vitro and In Vivo

Prevention of Venous Thrombotic Events in Adult Patients with Acute Lymphoblastic Leukemia Treated in a Pediatric-Inspired Protocol - a Graall Study

The HIV Protease Inhibitor Nelfinavir in Combination with Bortezomib and Dexamethasone (NVd) Has Excellent Activity in Patients with Advanced, Proteasome Inhibitor-Refractory Multiple Myeloma: A Multicenter Phase II Trial (SAKK 39/13)

The Upper Age Limit for a Pediatric-Inspired Therapy in Younger Adults with Ph-Negative Acute Lymphoblastic Leukemia (ALL)? Analysis of the Graall-2005 Study

Stem Cell Mobilization Chemotherapy with Gemcitabine Is Effective and Safe in Myeloma Patients with Bortezomib Induced Neurotoxicity

SAKK 65/08: A Phase I Dose Escalation Study of Bortezomib in Combination with Nelfinavir in Patients with Advanced Hematologic Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only